Alnylam Pharmaceuticals (NASDAQ:ALNY) Hits New 1-Year Low – Time to Sell?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) shares reached a new 52-week low on Thursday . The company traded as low as $225.49 and last traded at $220.3510, with a volume of 185433 shares. The stock had previously closed at $286.62.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on ALNY. Truist Financial reduced their price objective on shares of Alnylam Pharmaceuticals from $505.00 to $410.00 and set a “buy” rating for the company in a report on Monday, July 13th. Morgan Stanley raised their price target on shares of Alnylam Pharmaceuticals from $370.00 to $400.00 and gave the stock an “equal weight” rating in a research note on Friday, July 10th. Citigroup initiated coverage on Alnylam Pharmaceuticals in a research note on Tuesday, May 19th. They issued a “buy” rating and a $380.00 price objective on the stock. Royal Bank Of Canada cut their target price on Alnylam Pharmaceuticals from $450.00 to $445.00 and set an “outperform” rating for the company in a research report on Friday, May 1st. Finally, JPMorgan Chase & Co. lowered their price target on Alnylam Pharmaceuticals from $420.00 to $400.00 and set an “overweight” rating on the stock in a research report on Wednesday, July 22nd. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have given a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $452.13.

Alnylam Pharmaceuticals Price Performance

The company has a market capitalization of $28.38 billion, a price-to-earnings ratio of 58.41 and a beta of 0.27. The company has a current ratio of 3.13, a quick ratio of 3.06 and a debt-to-equity ratio of 0.94. The company has a 50 day moving average price of $291.70 and a 200 day moving average price of $313.42.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.63 by $0.21. The business had revenue of $1.29 billion for the quarter, compared to analyst estimates of $1.32 billion. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.The firm’s revenue for the quarter was up 66.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.51) earnings per share. As a group, equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post 7.35 earnings per share for the current year.

Insider Transactions at Alnylam Pharmaceuticals

In other news, Director David E. I. Pyott sold 3,830 shares of the firm’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $299.18, for a total value of $1,145,859.40. Following the transaction, the director owned 1,582 shares of the company’s stock, valued at approximately $473,302.76. This trade represents a 70.77% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.86% of the company’s stock.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Large investors have recently bought and sold shares of the business. MV Capital Management Inc. acquired a new stake in Alnylam Pharmaceuticals during the 4th quarter worth $25,000. Caitong International Asset Management Co. Ltd bought a new stake in Alnylam Pharmaceuticals in the third quarter valued at about $29,000. HM Payson & Co. bought a new stake in Alnylam Pharmaceuticals in the fourth quarter valued at about $27,000. Golden State Wealth Management LLC lifted its stake in Alnylam Pharmaceuticals by 100.0% in the fourth quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 36 shares during the period. Finally, Manchester Capital Management LLC lifted its stake in Alnylam Pharmaceuticals by 600.0% in the fourth quarter. Manchester Capital Management LLC now owns 84 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 72 shares during the period. 92.97% of the stock is currently owned by institutional investors and hedge funds.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.